Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Myriad Genetics (MYGN) PT Raised to $23 at Jefferies
August 9, 2017 8:40 AM EDTJefferies raised its price target on Myriad Genetics (NASDAQ: MYGN) to $23.00 (from $21.00) while maintaining a Hold rating. MYGN's initial FY18 revenue outlook fell ~$30M below consensus, owing to ASP headwinds it will absorb in hereditary cancer from steps taken to secure LT, fixed-price... More
Myriad Genetics (MYGN) Tops Q4 EPS by 4c
August 8, 2017 4:23 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.04 better than the analyst estimate of $0.26. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $193.74 million.
GUIDANCE:
Myriad Genetics sees FY2018 EPS of $1.00-$1.05. Myriad Genetics sees FY2018... More
